| |
| |
|
| Insider
Information: |
Bencherif Merouane |
| Relationship: |
SVP, Preclinical Resea... |
| City: |
Winston-Salem |
| State: |
NC |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
15,938 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$8,149 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
15,938 |
|
|
| Total
Value |
$8,149 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Gyre Therapeutics |
GYRE |
SVP, Preclinical Resea... |
2012-05-18 |
15,938 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
21 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GYRE |
Gyre Therapeutics |
SVP, Preclinical Research |
• – – |
2012-05-18 |
4 |
OE |
$2.93 |
$46,698 |
D/D |
15,938 |
15,938 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
SVP, Preclinical Research |
• – – |
2011-01-19 |
4 |
S |
$27.09 |
$818,257 |
D/D |
(30,203) |
0 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
SVP, Preclinical Research |
• – – |
2011-01-19 |
4 |
OE |
$1.75 |
$83,069 |
D/D |
30,203 |
30,203 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
SVP, Preclinical Research |
• – – |
2011-01-18 |
4 |
S |
$27.17 |
$619,476 |
D/D |
(22,800) |
0 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
SVP, Preclinical Research |
• – – |
2011-01-18 |
4 |
OE |
$5.55 |
$126,540 |
D/D |
22,800 |
22,800 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
SVP, Preclinical Research |
• – – |
2010-12-10 |
4 |
OE |
$2.93 |
$192,535 |
D/D |
32,093 |
32,093 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
SVP, Preclinical Research |
• – – |
2010-12-10 |
4 |
S |
$24.05 |
$771,955 |
D/D |
(32,093) |
0 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2010-01-15 |
4 |
S |
$20.51 |
$1,499,452 |
D/D |
(73,108) |
0 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2010-01-15 |
4 |
OE |
$1.75 |
$328,301 |
D/D |
73,108 |
73,108 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2010-01-04 |
4 |
S |
$20.81 |
$160,946 |
D/D |
(7,735) |
0 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-12-16 |
4 |
S |
$21.93 |
$340,663 |
D/D |
(15,532) |
7,735 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-12-16 |
4 |
OE |
$8.51 |
$132,177 |
D/D |
15,532 |
23,267 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-12-15 |
4 |
S |
$22.19 |
$178,724 |
D/D |
(8,056) |
7,735 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-12-15 |
4 |
OE |
$8.51 |
$68,557 |
D/D |
8,056 |
15,791 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-12-14 |
4 |
S |
$22.44 |
$290,367 |
D/D |
(12,935) |
7,735 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-12-14 |
4 |
OE |
$2.93 |
$65,615 |
D/D |
12,935 |
20,670 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-07-28 |
4 |
OE |
$1.75 |
$93,734 |
D/D |
41,213 |
48,948 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-07-28 |
4 |
S |
$10.39 |
$428,133 |
D/D |
(41,213) |
7,735 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-07-27 |
4 |
S |
$10.14 |
$428,717 |
D/D |
(42,271) |
7,735 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical Research |
• – – |
2009-07-27 |
4 |
OE |
$1.75 |
$146,936 |
D/D |
42,271 |
50,006 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
VP, Preclinical ResearchOffice |
• – – |
2006-04-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,735 |
|
- |
|
21 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
